# Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

> **NCT00718523** · PHASE2 · TERMINATED · sponsor: **Translational Research in Oncology** · enrollment: 170 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** AMG 479
- **DRUG:** AMG 479 Placebo

## Key facts

- **NCT ID:** NCT00718523
- **Lead sponsor:** Translational Research in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2013-09
- **Final completion:** 2014-11
- **Target enrollment:** 170 (ACTUAL)
- **Why stopped:** The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.
- **Last updated:** 2016-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718523, "Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00718523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*